NL-OMON48234已完成不适用
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolation - BioVAD study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Diagnosis of paroxysmal or persistent AF as defined by the 2016 ESC
- •guidelines for the management of atrial fibrillation
- •2. Subject scheduled to undergo PVI within 6 months
- •3. Subject willing and able to comply with the follow-up requirements of the
- •4. Written informed consent obtained from subject aged 18 years or older
排除标准
- •1. Diagnosis of long-standing persistent AF as defined by the 2016 ESC
- •guidelines for the management of atrial fibrillation
- •2. Subjects implanted with a previous ICM, pacemaker, ICD, or cardiac
- •resynchronization therapy device
- •3. Subjects with an active infection
- •4. Subjects enrolled in another clinical study which may confound the results
- •of this study
- •5. Subjects with a life expectancy of <1 year due to any condition
研究者
相似试验
尚未招募
不适用
BioMonitor III: Validation of the Atrial fibrillation Detecting algorithm in patients undergoing pulmonary vein isolatioParoxysmal and persistent atrial fibrillationNL-OMON23516Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands30
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-005086-12-HUOctapharma AG216
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globuliEUCTR2012-005086-12-ATOctapharma AG216
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 18.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-005086-12-BGOctapharma AG234
进行中（未招募）
不适用
Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulirelapsing multiple sclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-005086-12-DEOctapharma AG216